From ligand structure to biological activity: modified estratrienes and their estrogenic and antiestrogenic effects in MCF-7 cells

被引:27
作者
Brooks, SC
Skafar, DF
机构
[1] Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA
[2] Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA
[3] Wayne State Univ, Sch Med, Karmanos Canc Inst, Detroit, MI 48201 USA
关键词
steroid; estradiol; estratriene; SERMs; structure; activity;
D O I
10.1016/j.steroids.2004.03.014
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A variety of compounds, including the selective estrogen receptor (ER) modulators tamoxifen and raloxifene, phytoestrogens such as genistein, and xenoestrogens such as bisphenol, bind to the estrogen receptor and elicit biological responses. Structural studies have linked the altered activity of compounds such as 4-hydroxytamoxifen, raloxifene, genistein, and tetrahydrochrysene, which have substantially different structures from estradiol (E2), to differences in the positioning of the critical "helix 12" within the ligand-binding domain (LBD) of the ER-ligand complex. However, subtle permutations of the E2 molecule would also be expected to modulate the pattern of responses within a cell. Forty-two ligands were constructed by the addition or relocation of double bonds, hydroxyl, keto, amino, and nitro substituents throughout the estra-1,3,5(10)-triene (estratriene) ring system. In this review, we summarize the effects of subtle changes in the estratriene molecule on the ability of the receptor complex to stimulate the growth of MCF-7 cells, or affect the expression of four estrogen-regulated genes (progesterone receptor, pS2 protein, cathepsin D, and tissue plasminogen activator), as well as undergo nuclear processing and downregulate ERalpha mRNA. The affinity of these ligands for, and mechanism of their binding with, the ERalpha have been measured, along with their effect on the conformation of the ER-ERE complex. In particular, two A-ring isomers of E2, 2- and 4-hydroxyestratriene-17beta-ol, display gene selective activity within MCF-7 cells which is dependent on complex endogenous promoters, an intact AF-2 and is sensitive to the level of SRC-1. Both of these A-ring isomers function as antiestrogens. Molecular modeling of these two A-ring isomers complexed with the ER ligand-binding domain supports the idea that the conformation of the LBD is affected by subtle changes in the estratriene structure. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:401 / 418
页数:18
相关论文
共 103 条
[1]   STEROID ANTAGONISTS - SATELLITE WORKSHOP OF THE 8TH INTERNATIONAL-CONGRESS OF ENDOCRINOLOGY, KYODAI-KAIKAN, KYOTO, JAPAN [J].
AGARWAL, MK ;
RAYNAUD, JP .
FEBS LETTERS, 1989, 245 (1-2) :1-3
[2]   STEROID-RECEPTOR STRUCTURE AND ANTIHORMONE DRUG DESIGN [J].
AGARWAL, MK .
BIOCHEMICAL PHARMACOLOGY, 1992, 43 (11) :2299-2306
[3]   2-ARYLINDENES AND 2-ARYLINDENONES - MOLECULAR-STRUCTURES AND CONSIDERATIONS IN THE BINDING ORIENTATION OF UNSYMMETRICAL NONSTEROIDAL LIGANDS TO THE ESTROGEN-RECEPTOR [J].
ANSTEAD, GM ;
WILSON, SR ;
KATZENELLENBOGEN, JA .
JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (09) :2163-2171
[4]   The estradiol pharmacophore: Ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site [J].
Anstead, GM ;
Carlson, KE ;
Katzenellenbogen, JA .
STEROIDS, 1997, 62 (03) :268-303
[5]   GENE-REGULATION BY STEROID-HORMONES [J].
BEATO, M .
CELL, 1989, 56 (03) :335-344
[6]   ESTROGEN-RESPONSIVE ELEMENT OF THE HUMAN PS2 GENE IS AN IMPERFECTLY PALINDROMIC SEQUENCE [J].
BERRY, M ;
NUNEZ, AM ;
CHAMBON, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (04) :1218-1222
[7]   ROLE OF THE 2 ACTIVATING DOMAINS OF THE ESTROGEN-RECEPTOR IN THE CELL-TYPE AND PROMOTER-CONTEXT DEPENDENT AGONISTIC ACTIVITY OF THE ANTIESTROGEN 4-HYDROXYTAMOXIFEN [J].
BERRY, M ;
METZGER, D ;
CHAMBON, P .
EMBO JOURNAL, 1990, 9 (09) :2811-2818
[8]   CRYSTAL-STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE HUMAN NUCLEAR RECEPTOR RXR-ALPHA [J].
BOURGUET, W ;
RUFF, M ;
CHAMBON, P ;
GRONEMEYER, H ;
MORAS, D .
NATURE, 1995, 375 (6530) :377-382
[9]  
BOWLER J, 1989, Steroids, V54, P71, DOI 10.1016/0039-128X(89)90076-7
[10]  
BROOKS SC, 1987, CANCER RES, V47, P4623